ATE489966T1 - Verbundsuperimmunogen zur verwendung als bifunktioneller impfstoff (tat-gp160) zur behandlung von aids - Google Patents
Verbundsuperimmunogen zur verwendung als bifunktioneller impfstoff (tat-gp160) zur behandlung von aidsInfo
- Publication number
- ATE489966T1 ATE489966T1 AT02772502T AT02772502T ATE489966T1 AT E489966 T1 ATE489966 T1 AT E489966T1 AT 02772502 T AT02772502 T AT 02772502T AT 02772502 T AT02772502 T AT 02772502T AT E489966 T1 ATE489966 T1 AT E489966T1
- Authority
- AT
- Austria
- Prior art keywords
- superimmunogen
- tat
- aids
- compound
- treatment
- Prior art date
Links
- 230000001588 bifunctional effect Effects 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 208000030507 AIDS Diseases 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 230000001364 causal effect Effects 0.000 abstract 1
- 239000002131 composite material Substances 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 231100000110 immunotoxic Toxicity 0.000 abstract 1
- 230000002625 immunotoxic effect Effects 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00113—Growth factors
- A61K39/001134—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00113—Growth factors
- A61K39/001135—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
- A61K39/001151—Apoptosis related proteins, e.g. survivin or livin p53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/812—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/82—Colon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/892—Reproductive system [uterus, ovaries, cervix, testes]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Toxicology (AREA)
- Vascular Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0110751A FR2828404B1 (fr) | 2001-08-10 | 2001-08-10 | Superimmunogene composite a usage vaccinal bifonctionnel pour le traitement des maladies associees a un desordre tissulaire stromal |
| PCT/FR2002/002853 WO2003013593A2 (fr) | 2001-08-10 | 2002-08-09 | Superimmunogene composite a usage vaccinal bifonctionnel pour le traitement des maladies associees a un desordre tissulaire stromal |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE489966T1 true ATE489966T1 (de) | 2010-12-15 |
Family
ID=8866487
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02772502T ATE489966T1 (de) | 2001-08-10 | 2002-08-09 | Verbundsuperimmunogen zur verwendung als bifunktioneller impfstoff (tat-gp160) zur behandlung von aids |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20040185058A1 (de) |
| EP (1) | EP1427441B1 (de) |
| JP (1) | JP2005502647A (de) |
| CN (1) | CN1568197A (de) |
| AT (1) | ATE489966T1 (de) |
| AU (1) | AU2002337268B2 (de) |
| CA (1) | CA2456802A1 (de) |
| DE (1) | DE60238492D1 (de) |
| DK (1) | DK1427441T3 (de) |
| ES (1) | ES2355711T3 (de) |
| FR (1) | FR2828404B1 (de) |
| WO (1) | WO2003013593A2 (de) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7887811B2 (en) * | 2005-05-24 | 2011-02-15 | Neovacs | Method for preparing a stable immunogenic product comprising antigenic heterocomplexes of TNFα and a carrier protein |
| SA110310528B1 (ar) | 2009-06-22 | 2014-07-02 | Wyeth Llc | التركيبات المولدة للمناعة لأنتيجينات ستافيلوكوكس أوريس |
| SG10201406432RA (en) | 2009-06-22 | 2014-11-27 | Wyeth Llc | Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions |
| CN105327350A (zh) * | 2014-07-23 | 2016-02-17 | 中国科学院上海巴斯德研究所 | 泛素化途径相关因子在调控辅助性t细胞功能中的应用 |
| CN120676955A (zh) | 2022-12-09 | 2025-09-19 | Dys免疫治疗公司 | 产生抗hiv特异性中和抗体和/或抗hiv细胞毒性t细胞的复合aids疫苗 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2677654B1 (fr) * | 1991-06-17 | 1995-11-17 | Pasteur Merieux Serums Vacc | Composes a effet immunogene anti-cytokine, a effet immunogene anticytostatique ou a effet vaccinal anti-infection a hiv. |
| JP3958360B2 (ja) * | 1995-02-24 | 2007-08-15 | キャンタブ ファーマシューティカルズ リサーチ リミティド | 免疫治療剤として役立つポリペプチド及びポリペプチド調製の方法 |
| ATE196255T1 (de) * | 1995-03-08 | 2000-09-15 | Neovacs | Von einem retroviralen regulationsprotein abstammende, detoxifierte immunogene, dagegen gerichtete antikörper, verfahren zur deren herstellung und diese immunogene oder antikörper enthaltende, pharmazeutische zusammensetzungen. |
| US5965532A (en) * | 1996-06-28 | 1999-10-12 | Trustees Of Tufts College | Multivalent compounds for crosslinking receptors and uses thereof |
| FR2773156B1 (fr) * | 1997-12-26 | 2000-03-31 | Biovacs Inc | Nouveaux immunogenes anti-retroviraux (toxoides), nouveaux procedes de preparation et application a la prevention et au traitement du sida |
| FR2781158B1 (fr) * | 1998-07-15 | 2002-12-13 | Vacs Internat | Nouvelles proteines modifiees immunogenes non immunosuppressives, leur procede de preparation et leurs applications |
| DE69929232T2 (de) * | 1998-10-21 | 2006-08-31 | The United States Government As Represented By The Department Of Health And Human Services | Virusähnliche partikel zur induktion von autoantikörpern |
| WO2000078334A1 (en) * | 1999-06-17 | 2000-12-28 | University Of Maryland Biotechnology Institute | Chimeric chemokine-antigen polypeptides and uses therefor |
| FR2802426B1 (fr) * | 1999-12-15 | 2004-04-02 | Neovacs | Utilisation de proteines immunogenes immunosuppressives et/ou angiogeniques rendues inactives, pour la production d'iga secretoires |
| BR0107972A (pt) * | 2000-01-31 | 2002-11-05 | Smithkline Beecham Biologicals | Uso de uma proteìna ou polinucleotìdeo tat do hiv, nef do hiv, ou tat do hiv ligado(a) a uma proteìna ou polinucleotìdeo nef do hiv (nef-tat), e de uma proteìna ou polinucleotìdeo gp120 do hiv, método para imunizar um ser humano contra o hiv, e, composição de vacina para o uso humano |
| FR2812813B1 (fr) * | 2000-08-09 | 2004-11-26 | Neovacs | Utilisation d'immunogenes pour traiter ou prevenir au sein des tumeurs malignes les dereglements immunitaires induits par des facteurs extracellulaires |
-
2001
- 2001-08-10 FR FR0110751A patent/FR2828404B1/fr not_active Expired - Fee Related
-
2002
- 2002-08-09 DE DE60238492T patent/DE60238492D1/de not_active Expired - Lifetime
- 2002-08-09 EP EP02772502A patent/EP1427441B1/de not_active Expired - Lifetime
- 2002-08-09 JP JP2003518597A patent/JP2005502647A/ja active Pending
- 2002-08-09 WO PCT/FR2002/002853 patent/WO2003013593A2/fr not_active Ceased
- 2002-08-09 CN CNA028200845A patent/CN1568197A/zh active Pending
- 2002-08-09 US US10/486,329 patent/US20040185058A1/en not_active Abandoned
- 2002-08-09 DK DK02772502.7T patent/DK1427441T3/da active
- 2002-08-09 AT AT02772502T patent/ATE489966T1/de active
- 2002-08-09 CA CA002456802A patent/CA2456802A1/fr not_active Abandoned
- 2002-08-09 AU AU2002337268A patent/AU2002337268B2/en not_active Ceased
- 2002-08-09 ES ES02772502T patent/ES2355711T3/es not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1568197A (zh) | 2005-01-19 |
| WO2003013593A2 (fr) | 2003-02-20 |
| DE60238492D1 (de) | 2011-01-13 |
| WO2003013593A3 (fr) | 2003-10-02 |
| US20040185058A1 (en) | 2004-09-23 |
| EP1427441A2 (de) | 2004-06-16 |
| AU2002337268B2 (en) | 2007-02-01 |
| CA2456802A1 (fr) | 2003-02-20 |
| EP1427441B1 (de) | 2010-12-01 |
| JP2005502647A (ja) | 2005-01-27 |
| DK1427441T3 (da) | 2011-02-28 |
| ES2355711T3 (es) | 2011-03-30 |
| FR2828404A1 (fr) | 2003-02-14 |
| FR2828404B1 (fr) | 2005-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE426412T1 (de) | Adjuvante influenza-vakzine | |
| ATE542829T1 (de) | Impfstoff | |
| WO2004060308A3 (en) | Thiosemicarbazones as anti-virals and immunopotentiators | |
| CY1106357T1 (el) | Παραγωγα αδαμαντανιου για τη θepαπεια φλεγμονωδων, ανοσολογικων και καρδιαγγειακων ασθενειων | |
| EP1504112A4 (de) | Entwicklung einer vakzine zur prävention von infektionen mit dem filovirus bei primaten | |
| ATE476983T1 (de) | Immunostimulierende polynukleotide sequenzen zur verwendung bei der verhinderung und behandlung von viralen erkrankungen der atemwege | |
| CY1107628T1 (el) | Ανθρωπινα ctla-4 αντισωματα και χρησεις αυτων | |
| ATE508735T1 (de) | Pulmonale verabreichung von aminoglykosiden | |
| ATE267830T1 (de) | Als cox-hemmer verwendbare sulfonylphenylpyrazol- verbindungen | |
| DE60137337D1 (de) | Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene | |
| CY1111567T1 (el) | Ενδιαμεσα διβενζο (b,f) αζεπινης | |
| MA32388B1 (fr) | Immunomodulation par des inhibiteurs d'iap | |
| PT1409692E (pt) | Novos péptidos do derivados da proteína g do vírus respiratório sincicial (vrs) e sua utilização numa vacina | |
| MXPA02007478A (es) | Vacuna contra el virus de inmunodeficiencia humana. | |
| WO2005028496A3 (en) | Vaccine for treatment and prevention of herpes simplex virus infection | |
| NO20050091L (no) | Fremgangsmater for fremstilling av fibrinogen | |
| ATE458496T1 (de) | Hiv-vakzine und anwendungsverfahren | |
| SE0300034D0 (sv) | Use of strains of the parapox ovis virus for producting antiviral pharmaceuticals and anticancer pharmaceuticals | |
| DE60238492D1 (de) | VERBUNDSUPERIMMUNOGEN ZUR VERWENDUNG ALS BIFUNKTIONELLER IMPFSTOFF (Tat-gp160) ZUR BEHANDLUNG VON AIDS | |
| MX2009005026A (es) | Anticuerpos anti-tsg101 y sus usos para tratamiento de infecciones virales. | |
| YU68602A (sh) | Monoklonska antitela na humani ldl receptor, njihova produkcija i korišćenje | |
| ES2502366T3 (es) | Inducción de inmunidad tumoral por variantes de proteína de unión a folato | |
| WO2003052122A3 (en) | Gp41 inhibitor | |
| MX2007002659A (es) | Composicion vacunal contra el virus de la hepatitis c. | |
| WO2020053742A3 (en) | Anti-hla-hbv peptide antibodies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1427441 Country of ref document: EP |